Provectus Pharmaceuticals Completes Patient Accrual in Phase 2C Clinical Trial of PH-10 for Psoriasis
Provectus Pharmaceuticals Completes Patient Accrual in Phase 2C Clinical Trial of PH-10 for Psoriasis
KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Pharmaceuticals has completed patient accrual in its Phase 2C clinical trial of PH-10 for psoriasis.
Read more on Business Wire
Categories: Breast Cancer Information Tags: Accrual, Clinical, Completes, patient, PH10, Pharmaceuticals, Phase, Provectus, Psoriasis, Trial
Peregrine Reports Promising Interim Survival Data From Phase II Cotara Recurrent GBM Trial
Peregrine Reports Promising Interim Survival Data From Phase II Cotara Recurrent GBM Trial
TUSTIN, CA–(Marketwire – 05/19/11) – Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM – News ), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced interim median overall survival of 8.8 months (38 weeks, 40 patients at first relapse) from a Phase II trial for Cotara in recurrent glioblastoma …
Read more on Marketwire via Yahoo! Finance
Categories: Breast Cancer Information Tags: Cotara, Data, From, Interim, Peregrine, Phase, Promising, recurrent, Reports, Survival, Trial
Pfizer’s axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints
Pfizer’s axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints
Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma, axitinib significantly extended progression-free survival at the 47th Annual American Society of Clinical Oncology meeting in Chicago from June 3-7, 2011.
Read more on News-Medical-Net
Categories: Breast Cancer Information Tags: advanced, axitinib, carcinoma, Cell, endpoints, meets, Pfizer's, Phase, Primary, Renal, Trial
CytRx Begins Phase 1b Clinical Trial with INNO-206 in Patients with Advanced Solid Tumors
CytRx Begins Phase 1b Clinical Trial with INNO-206 in Patients with Advanced Solid Tumors
CytRx Corporation , a biopharmaceutical company specializing in oncology, today announced that it has initiated an open-label Phase 1b safety and dose escalation clinical trial with INNO-206 at the Sarcoma Oncology Center in Santa Monica, California.
Read more on Business Wire via Yahoo! Finance
Categories: Breast Cancer Information Tags: advanced, Begins, Clinical, CytRx, INNO206, Patients, Phase, SOLiD, Trial, Tumors
Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine
Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine
Vical Incorporated announced today the receipt of Scientific Advice from the European Medicines Agency (EMA) recommending practical efficacy endpoints for a Phase 3 trial of the company’s TransVax™ therapeutic cytomegalovirus (CMV) vaccine.
Read more on News-Medical-Net
Categories: Breast Cancer Awareness Tags: advice, Phase, receives, Scientific, Therapeutic, TransVax, Trial, vaccine, Vical